Neurologists' attitudes regarding rt-PA for acute ischemic stroke.
We studied the attitudes of 238 Texas neurologists regarding the use of recombinant tissue plasminogen activator (rt-PA). The results show that 38 (16%) had treated stroke patients with rt-PA, and 97% of these would do so again. In the group that had not treated patients, 60% would treat if a suitable candidate presented. We conclude that soon after FDA approval of rt-PA, two-thirds of survey respondents were using or were planning to use this therapy. Those neurologists who have used rt-PA for stroke report a positive experience.
Villar-Cordova
C
C
Department of Neurology, The University of Texas Medical School at Houston, 77030, USA.
Morgenstern
L B
LB
Barnholtz
J S
JS
Frankowski
R F
RF
Grotta
J C
JC
D019538:Health Care Surveys; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008875:Middle Aged; D009462:Neurology; D011994:Recombinant Proteins / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator